Basic Information
Strain Name
U87-MG Gt(AAVS1)tm1(luciferase)/Bcgen
Stock Number
310675
Common Name
B-CAG-luc U87-MG
Disease
Glioblastoma
Species
Homo sapiens, human
Culture Properties
Adherent
Resistence
Puromycin, 0.5μg/mL
Culture medium
MEM+10%FBS+1% L-Glutamine+1% NEAA+1% Sodium pyruvate+1%HEPES
Frozen
90% FBS+10% DMSO
Notice
Biocytogen provides engineering service to generate the humanized tumor cell lines from customer’s own cell lines. Our humanized tumor cell lines are for pharmacology services ONLY.
-
Targeting Strategy
-
Gene targeting strategy for B-CAG-luc U87-MG. The hAAVS1 locus of the huamn was inserted into the stop-CAG-Pr-luciferase-PA- LoxP-PuroR- LoxP sequence in B-CAG-luc U87-MG.
-
Details
-
Tumor Growth Curve & Body Weight Changes
Subcutaneous xenograft tumor growth of B-CAG-luc U87-MG cells. B-CAG-luc U87-MG cells (5×106) were subcutaneously implanted into the B-NDG mice (female, 5-8 week-old, n=5).Tumor size and mice body weight were measured twice a week. (A) Tumor average volume ± SEM, (B) Mice body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5a X b2, where a and b were the long and short diameters of the tumor, respectively. As shown in panel A, B-CAG-luc U87-MG were able to establish tumor in vivo and can be used for efficacy study.
